Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Measured and genetically predicted plasma YKL-40 levels and melanoma mortality

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Transcriptome-wide association study reveals candidate causal genes for lung cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

    Research output: Contribution to journalReviewResearchpeer-review

  4. Reply to: Clinical impact of high platelet count and high hematocrit, by Marc Sorigue

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: High plasma levels of YKL-40 might be associated with mortality in patients with melanoma, and it is unknown if YKL-40 is causally related to mortality.

EXPERIMENTAL DESIGN: We studied two cohorts: 2618 patients with melanoma from hospital clinics and 1413 general population patients with melanoma, totalling 4031 patients followed up for mortality end-points for up to 20 years. All were genotyped for CHI3L1 rs4950928, highly predictive of lifelong plasma YKL-40, and plasma YKL-40 levels were measured in 2165 patients. We tested the hypotheses that measured and genetically predicted high plasma YKL-40 are associated with increased mortality in patients with melanoma.

RESULTS: For the hospital melanoma cohort, age- and sex-adjusted hazard ratios for death in individuals with measured plasma YKL-40 in the 96-100th percentile versus 1-95th percentile and per 10-percentile increase were 1.52 (95% confidence interval, 1.07-2.16) and 1.07 (1.02-1.11), respectively, most pronounced for patients with localised melanomas. Each C-allele of the CHI3L1 rs4950928 genotype was associated with plasma YKL-40 level increases of 32% in the hospital melanoma cohort (p = 6 × 10-48) and 43% in the general population melanoma cohort (p = 7 × 10-13). Multifactorially adjusted ratios for these increases in the combined cohorts were 1.04 (1.00-1.09) observationally for measured plasma YKL-40 and 0.98 (0.86-1.12) for the genetically predicted plasma YKL-40.

CONCLUSION: Measured, but not genetically predicted, increasing plasma YKL-40 was associated with increased mortality in patients with melanoma. Plasma YKL-40 is a marker but less likely to be a cause of increased mortality in patients with melanoma.

Original languageEnglish
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume121
Pages (from-to)74-84
ISSN0959-8049
DOIs
Publication statusPublished - Nov 2019

ID: 59139599